文献速递胸部肿瘤头颈与中枢神经肿瘤

伏美替尼(AST2818)对比吉非替尼一线治疗EGFR突变NSCLC的中枢神经系统疗效:FURLONG研究结果

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
PubMed 文献 · J Thorac Oncol · 2022-08-03

FURLONG研究是在中国55家医院开展的双盲随机3期试验,比较伏美替尼80 mg每日一次与吉非替尼250 mg每日一次一线治疗EGFR敏感突变阳性NSCLC。在133例基线中枢神经系统转移患者中,伏美替尼组中枢神经系统无进展生存期为20.8个月,吉非替尼组为9.8个月,风险比为0.40。

要点

  • 伏美替尼组中枢神经系统无进展生存期20.8个月,吉非替尼组9.8个月,风险比0.40。
  • 在60例可测量中枢神经系统病灶患者中,伏美替尼组中枢神经系统客观缓解率为91%,吉非替尼组为65%,比值比为6.82。
  • 伏美替尼组中枢神经系统缓解深度最小二乘均值为62%,吉非替尼组为39%,平均差异为23%。

核心结论

  • 在伴有中枢神经系统转移的EGFR突变NSCLC患者中,伏美替尼一线治疗的中枢神经系统无进展生存期、中枢神经系统客观缓解率和中枢神经系统缓解深度均优于吉非替尼。

研究设计与样本

  • FURLONG研究是一项在中国55家医院开展的双盲随机3期研究,共纳入358例患者,按1:1随机接受伏美替尼80 mg每日一次或吉非替尼250 mg每日一次治疗。
  • 所有患者在筛查时接受脑影像学检查,基线无症状且稳定的中枢神经系统转移患者构成预设的中枢神经系统亚组分析。

主要发现

  • 在133例(37%)可测量或不可测量中枢神经系统病灶患者中,伏美替尼组中枢神经系统无进展生存期为20.8个月(95%CI:15.2-25.3),吉非替尼组为9.8个月(95%CI:7.2-18.0),风险比为0.40(95%CI:0.23-0.71,P=0.0011)。
  • 在60例(17%)可测量中枢神经系统病灶患者中,伏美替尼组中枢神经系统客观缓解率为91%(95%CI:72-99),吉非替尼组为65%(95%CI:48-80),比值比为6.82(95%CI:1.23-37.67,P=0.0277)。
  • 伏美替尼组中枢神经系统缓解深度的最小二乘均值为62%(95%CI:51-72),吉非替尼组为39%(95%CI:30-47),平均差异为23%(95%CI:10-37,P=0.0011)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. We report the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study. METHODS: FURLONG was a randomized, double-blind, phase 3 study conducted in 55 hospitals in the People's Republic of China. Patients 1:1 randomly received furmonertinib 80 mg once daily or gefitinib 250 mg once daily treatment. At screening, all the patients underwent brain imaging examination. Patients with asymptomatic steady CNS metastases at baseline constituted this preplanned CNS subgroup analysis. RESULTS: A total of 358 patients were enrolled in the FURLONG study. In the 133 (37%) patients who had measurable or nonmeasurable CNS lesions, CNS progression-free survival was 20.8 months (95% confidence interval [CI]: 15.2-25.3) in the furmonertinib group and 9.8 months (95% CI: 7.2-18.0) in the gefitinib group (hazard ratio = 0.40 [95% CI: 0.23-0.71], p = 0.0011). In the 60 patients (17%) who had measurable CNS lesions, CNS objective response rate was 91% (95% CI: 72-99) with furmonertinib and 65% (95% CI: 48-80) with gefitinib (OR = 6.82 [95% CI: 1.23-37.67], p = 0.0277). The least-square mean of CNS depth of response was 62% (95% CI: 51-72) in the furmonertinib group and 39% (95% CI: 30-47) in the gefitinib group, the mean difference was 23% (95% CI: 10-37, p = 0.0011). CONCLUSIONS: Furmonertinib first-line treatment was found to have superior efficacy in CNS progression-free survival, CNS objective response rate, and CNS depth of response compared with gefitinib in patients with EGFR-mutated NSCLC with CNS metastases.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shi Y, Chen G, Wang X, et al. Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study. J Thorac Oncol. 2022. PMID: 35932953. doi:10.1016/j.jtho.2022.07.1143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。